12 resultat
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their
FIELD OF THE INVENTION
The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds.
BACKGROUND OF THE INVENTION
Copper is a normal component of the human brain, which contains
FIELD OF THE INVENTION
The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds.
BACKGROUND OF THE INVENTION
Copper is a normal component of the human brain, which contains
FIELD OF THE INVENTION
The present invention relates to a method of convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds.
BACKGROUND OF THE INVENTION
Copper is a normal component of the human brain, which contains about 370 mg
FIELD OF THE INVENTION
The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds.
BACKGROUND OF THE INVENTION
Copper is a normal component of the human brain, which contains
FIELD OF THE INVENTION
The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula
##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically
FIELD OF THE INVENTION
The present invention is directed to novel biocatalytic processes for the regio- and stereoselective conversion of selected aliphatic dinitriles into corresponding cyanocarboxylic acids. More particularly, the present invention provides methods for the conversion of
FIELD OF THE INVENTION
This application is a divisional application of U.S. non provisional application Ser. No. 10/599,899, filed on Feb.15, 2007, which claims the benefit of International application number PCT/IB2005/000873, filed on Apr. 1, 2005, which claims the benefit of U.S. provisional
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention concerns a method of using aminobenz amides as anticonvulsants, novel nitrobenzamides and amino benzamides prepared therefrom and compositions thereof which are useful anticonvulsants. More particularly, the invention concerns novel
FIELD OF THE INVENTION
This invention relates to substituted fused pyrazolecarboxylic acid arylamides and related compounds, such as substituted fused pyrazolecarboxylic acid arylamides that bind with high selectivity and high affinity to the benzodiazepine site of GABA.sub.A receptors. This
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national stage entry under 35 U.S.C. .sctn.371(b) of International Application No. PCT/EP2011/056986, filed May 2, 2011, which claims the benefit of European Patent Application Serial No. 10161546.6, filed Apr. 30, 2010 and European
BACKGROUND OF THE INVENTION
The present invention relates to a agents useful as excitatory amino acid antagonists. The quinoline and kynurenin derivatives of the present invention have affinity for the glycine binding site of the NMDA receptor. Compounds of the present invention should be usable for